ExoAtlet

ExoAtlet operates at the intersection of assistive medical devices, neurotechnology, rehabilitation services, and professional education. Its differentiation is not limited to exoskeleton hardware: the company combines several device lines, including EA Bambini, EA II Pro, EA Plus Pro, EA Pro, and EA Sofia, with a licensed Moscow education center and distance-learning capabilities for rehabilitation professionals. This model addresses a practical adoption barrier in the sector, namely the need to train clinicians and therapists to use exoskeletons across different patient conditions and recovery stages. The company’s positioning appears more clinically and institutionally focused than that of a consumer mobility-device business. The $5 million Series A in April 2018 and subsequent team expansion provide evidence of early investor and operating traction, but the absence of newer financing and market indicators makes it difficult to determine whether ExoAtlet is competing primarily through technology, clinical integration, geographic reach, or training infrastructure.

ExoAtlet’s clearest growth inflection point was its April 2018 Series A, when it raised $5 million from Cosmo and Company. The following year, the team expanded from 8 to 40 employees by March 2019, a fivefold increase that suggests investment in product development, commercial operations, clinical support, or education delivery. The company’s trajectory also reflects a broadening from exoskeleton design toward a fuller rehabilitation ecosystem. Its portfolio spans pediatric and professional-use devices, while its licensed education center provides both in-person and distance-based instruction for clinicians. That combination can support scale by helping healthcare providers adopt the technology rather than treating the exoskeleton as a standalone product. Consequently, the post-2019 trajectory is difficult to quantify.